Concert Pharma (CNCE) Reports Q3 EPS of $5.44

Concert Pharma (NASDAQ: CNCE) reported Q3 EPS of $5.44, versus ($0.51) reported last year. Revenue for the quarter came in at $143.8 million versus the consensus estimate of $11.7 thousand.

For earnings history and earnings-related data on Concert Pharma (CNCE) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• Duos Technologies Group, Inc. (DUOT) Tops Q2 EPS by 163c
• Barclays Upgrades Schott Pharma AG (1SXP:GR) to Overweight